Abstract
The impact of autoimmunity on the heart electrical activity is being more and more recognized, as clinical and experimental evidences demonstrate the association between the presence of pathogenic autoantibodies and cardiac repolarization. Long QT syndrome (LQTS) which manifests as prolongation of the repolarization measured as QT interval on the surface electrocardiogram, increases risk for ventricular arrhythmia particularly torsades de pointes. Here, we discuss current knowledge in the functional and molecular basis of autoantibody (anti-Ro/SSA antibodies)-induced QTc prolongation in patients with autoimmune diseases particularly connective tissue disease as well as in the general population subjects with torsades de pointes. Specifically, in vitro and in vivo experimental evidence is provided demonstrating that the human Ether-à-go-go-Related Gene, hERG, potassium channel conducting the rapidly activating delayed potassium current, IKr, is a target for anti-Ro/SSA antibodies, leading to action potential duration prolongation and QT interval lengthening on the surface electrocardiogram, thus predisposition to torsades de pointes. The predicted anti-Ro/SSA antibody binding sites have been identified on the hERG extracellular loop between S5/S6, thereby opening new avenues in the development of decoy peptide-based therapeutic approaches.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
El-Sherif N, Turitto G, Boutjdir M. Congenital long QT syndrome and torsade de pointes. Ann Noninvasive Electrocardiol. 2017;22(6):e12481.
El-Sherif N, Turitto G, Boutjdir M. Acquired long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol. 2018;41:414.
El-Sherif N, Turitto G. Torsade de pointes. Curr Opin Cardiol. 2003;18(1):6–13.
Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J. 1975;89(3):378–90.
Roden DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol. 2008;154(7):1502–7.
Farkas AS, Nattel S. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. Drugs. 2010;70(5):573–603.
Lerner MR, Boyle JA, Hardin JA, Steitz JA. Two novel classes of small ribonucleoproteins detected by antibodies associated with lupus erythematosus. Science. 1981;211(4480):400–2.
Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol. 2012;2012:606195.
Sim S, Wolin SL. Emerging roles for the Ro 60-kDa autoantigen in noncoding RNA metabolism. Wiley Interdiscip Rev RNA. 2011;2(5):686–99.
Kong HJ, Anderson DE, Lee CH, Jang MK, Tamura T, Tailor P, et al. Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol. 2007;179(1):26–30.
Higgs R, Lazzari E, Wynne C, Ni Gabhann J, Espinosa A, Wahren-Herlenius M, et al. Self protection from anti-viral responses--Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS One. 2010;5(7):e11776.
Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol. 2008;181(3):1780–6.
Lee AYS. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity. Rheumatol Int. 2017;37(8):1323–33.
Lee HC, Huang KT, Wang XL, Shen WK. Autoantibodies and cardiac arrhythmias. Heart Rhythm. 2011;8(11):1788–95.
Lazzerini PE, Capecchi PL, Laghi-Pasini F, Boutjdir M. Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias. Nat Rev Cardiol. 2017;14(9):521–35.
Bornholz B, Roggenbuck D, Jahns R, Boege F. Diagnostic and therapeutic aspects of beta1-adrenergic receptor autoantibodies in human heart disease. Autoimmun Rev. 2014;13(9):954–62.
Patel PA, Hernandez AF. Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy. Eur J Heart Fail. 2013;15(7):724–9.
Matsui S, Fu M. Pathological importance of anti-G-protein coupled receptor autoantibodies. Int J Cardiol. 2006;112(1):27–9.
Li J, Seyler C, Wiedmann F, Schmidt C, Schweizer PA, Becker R, et al. Anti-KCNQ1 K(+) channel autoantibodies increase IKs current and are associated with QT interval shortening in dilated cardiomyopathy. Cardiovasc Res. 2013;98(3):496–503.
Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G, et al. Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum. 2004;50(4):1248–52.
Lazzerini PE, Capecchi PL, Acampa M, Morozzi G, Bellisai F, Bacarelli MR, et al. Anti-Ro/SSA-associated corrected QT interval prolongation in adults: the role of antibody level and specificity. Arthritis Care Res (Hoboken). 2011;63(10):1463–70.
Lazzerini PE, Capecchi PL, Guideri F, Bellisai F, Selvi E, Acampa M, et al. Comparison of frequency of complex ventricular arrhythmias in patients with positive versus negative anti-Ro/SSA and connective tissue disease. Am J Cardiol. 2007;100(6):1029–34.
Lazzerini PE, Yue Y, Srivastava U, Fabris F, Capecchi PL, Bertolozzi I, et al. Arrhythmogenicity of anti-Ro/SSA antibodies in patients with torsades de pointes. Circ Arrhythm Electrophysiol. 2016;9(4):e003419.
Cimaz R, Stramba-Badiale M, Brucato A, Catelli L, Panzeri P, Meroni PL. QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block. Arthritis Rheum. 2000;43(5):1049–53.
Bourré-Tessier J, Clarke AE, Huynh T, Bernatsky S, Joseph L, Belisle P, et al. Prolonged corrected QT interval in anti-Ro/SSA-positive adults with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(7):1031–7.
Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S, et al. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol. 2008;18(2):153–60.
Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64(7):2319–27.
Guo YP, Wang CG, Liu X, Huang YQ, Guo DL, Jing XZ, et al. The prevalence of antinuclear antibodies in the general population of China: a cross-sectional study. Curr Ther Res Clin Exp. 2014;76:116–9.
Lazzerini PE, Capecchi PL, Guideri F, Acampa M, Selvi E, Bisogno S, et al. Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications. Basic Res Cardiol. 2008;103(1):1–11.
Boutjdir M, Lazzerini PE, Capecchi PL, Laghi-Pasini F, El-Sherif N. Potassium channel block and novel autoimmune-associated long QT syndrome. Card Electrophysiol Clin. 2016;8(2):373–84.
Yue Y, Castrichini M, Srivastava U, Fabris F, Shah K, Li Z, et al. Pathogenesis of the novel autoimmune-associated long-QT syndrome. Circulation. 2015;132(4):230–40.
Nakamura K, Katayama Y, Kusano KF, Haraoka K, Tani Y, Nagase S, et al. Anti-KCNH2 antibody-induced long QT syndrome: novel acquired form of long QT syndrome. J Am Coll Cardiol. 2007;50(18):1808–9.
Suzuki S, Satoh T, Yasuoka H, Hamaguchi Y, Tanaka K, Kawakami Y, et al. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol. 2005;170(1–2):141–9.
Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, et al. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur J Neurol. 2014;21(2):223–30.
Romi F, Suzuki S, Suzuki N, Petzold A, Plant GT, Gilhus NE. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol. 2012;259(7):1312–6.
Fabris F, Yue Y, Qu Y, Chahine M, Sobie E, Lee P, et al. Induction of autoimmune response to the extracellular loop of the HERG channel pore induces QTc prolongation in guinea pigs. J Physiol. 2016;594(21):6175–87.
Karnabi E, Boutjdir M. Role of calcium channels in congenital heart block. Scand J Immunol. 2010;72(3):226–34.
Strandberg LS, Cui X, Rath A, Liu J, Silverman ED, Liu X, et al. Congenital heart block maternal sera autoantibodies target an extracellular epitope on the alpha1G T-type calcium channel in human fetal hearts. PLoS One. 2013;8(9):e72668.
Ambrosi A, Sonesson SE, Wahren-Herlenius M. Molecular mechanisms of congenital heart block. Exp Cell Res. 2014;325(1):2–9.
Qu Y, Baroudi G, Yue Y, Boutjdir M. Novel molecular mechanism involving alpha1D (Cav1.3) L-type calcium channel in autoimmune-associated sinus bradycardia. Circulation. 2005;111(23):3034–41.
Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52(2):402–11.
Acknowledgement
Supported in part by Cardiovascular Research program, a MERIT Award Number I01BX007080 from Biomedical Laboratory Research & Development Service of Veterans Affairs Office of Research and Development (MB), and the Narrows Institute for Biomedical Research and Education (NES).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Boutjdir, M., Lazzerini, P.E., Capecchi, P.L., Laghi-Pasini, F., El-Sherif, N. (2020). Pathogenesis of Autoimmune-Associated Long QT Syndrome. In: El-Sherif, N. (eds) Cardiac Repolarization. Springer, Cham. https://doi.org/10.1007/978-3-030-22672-5_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-22672-5_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-22671-8
Online ISBN: 978-3-030-22672-5
eBook Packages: MedicineMedicine (R0)